REVIEW
Add like
Add dislike
Add to saved papers

Vasculitis Following Influenza Vaccination: A Review of the Literature.

BACKGROUND: Influenza vaccine is safe and effective for the general population as well as for patients with autoimmune diseases. However, although rare, vasculitis has been reported as an adverse event following influenza vaccination.

OBJECT: The aims of this literature review were to identify patients who developed vasculitis following influenza vaccination and to clarify the clinical manifestations of vasculitis in these patients.

METHODS: Using the PubMed database and search engine, we performed a search of the Englishlanguage literature by combining the term influenza vaccination with each term for a specific form of vasculitis from January 1966 through April 2016.

RESULTS: A total of 65 patients who developed vasculitis after influenza vaccination were identified from 45 published reports. The majority of patients were elderly, and the patients were predominantly female. The vasculitides included large vessel vasculitis (13 patients), medium vessel vasculitis (2), small vessel vasculitis (42), single organ vasculitis (5), vasculitis associated with systemic disease (1), and vasculitis associated with probable etiology (1). Although the majority of patients achieved complete recovery or remission, there were 3 deaths in patients with ANCA-associated vasculitis and severe long-term sequelae developed in 3 patients (1 with granulomatosis with polyangiitis, 1 with IgA vasculitis and 1 with unclassified small vessel vasculitis).

CONCLUSION: Since vasculitis following influenza vaccination has been only rarely reported, routine influenza vaccination should not be restricted. However, caution should be required when patients with small vessel vasculitis, especially with ANCA-associated vasculitis following influenza vaccination or with post-influenza vaccination-reactivated IgA vasculitis, receive influenza vaccination again.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app